Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI).

During the last two decades, biomarker research has benefited from the introduction of new proteomic analytical techniques. In this article, we review the application of surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectroscopy in urologic cancer research. After reviewing the literature from MEDLINE on proteomics and urologic oncology, we found that SELDI-TOF is an emerging proteomic technology in biomarker discovery that allows for rapid and sensitive analysis of complex protein mixtures. SELDI-TOF is a novel proteomic technology that has the potential to contribute further to the understanding and clinical exploitation of new, clinically relevant biomarkers.

[1]  D J O'Kane,et al.  A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. , 2000, The Journal of urology.

[2]  M. Stoeckli,et al.  Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry. , 1999, Analytical chemistry.

[3]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[4]  N. Anderson,et al.  Proteomics: applications in basic and applied biology. , 2000, Current opinion in biotechnology.

[5]  A. Shabsigh,et al.  Current concepts in biomarker technology for bladder cancers. , 2000, Clinical chemistry.

[6]  A. Vlahou,et al.  Proteomic approaches to biomarker discovery in prostate and bladder cancers , 2001, Proteomics.

[7]  David Sidransky,et al.  Detection of bladder cancer recurrence by microsatellite analysis of urine , 1997, Nature Medicine.

[8]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[9]  Katz,et al.  Biomarkers of renal cell carcinoma. Past and future considerations. , 2000, Urologic oncology.

[10]  A. K. Agarwal,et al.  Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. , 1999, The Journal of urology.

[11]  E. Petricoin,et al.  Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip , 2000 .

[12]  S M Hanash,et al.  Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers , 2001, Annals of the New York Academy of Sciences.

[13]  S M Hanash,et al.  Biomedical applications of two‐dimensional electrophoresis using immobilized pH gradients: Current status , 2000, Electrophoresis.

[14]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[15]  Rolf Apweiler,et al.  The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000 , 2000, Nucleic Acids Res..

[16]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[17]  C Coley,et al.  Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. , 2001, Urology.

[18]  M. Mann,et al.  Electrospray ionization for mass spectrometry of large biomolecules. , 1989, Science.

[19]  D. Hochstrasser,et al.  Current challenges and future applications for protein maps and post‐translational vector maps in proteome projects , 1996, Electrophoresis.

[20]  Marc R. Wilkins,et al.  Proteome Research: New Frontiers in Functional Genomics , 1997, Principles and Practice.

[21]  M. Marberger,et al.  Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. , 1999, The Journal of urology.

[22]  E. Fung,et al.  Protein biochips for differential profiling. , 2001, Current opinion in biotechnology.

[23]  Ronald C. Beavis,et al.  Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. , 1991, Analytical chemistry.

[24]  L. Kiemeney,et al.  Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. , 2001, Urology.

[25]  P. J. Monardo,et al.  A distributed system for two-dimensional gel analysis , 1994, Comput. Appl. Biosci..

[26]  Da-Jung Ha.  The ProteinChip System from Ciphergen: a new technique for rapid, micro-scale protein biology. , 2000 .

[27]  G. Wright,et al.  Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.

[28]  Adam Z. Stieg,et al.  Mass Spectroscopy as a Discovery Tool for Identifying Serum Markers for Prostate Cancer , 2001 .

[29]  Uwe Claussen,et al.  Mass spectrometry meets chip technology: A new proteomic tool in cancer research? , 2001, Electrophoresis.

[30]  A. Görg,et al.  The current state of two‐dimensional electrophoresis with immobilized pH gradients , 2000, Electrophoresis.

[31]  R D Appel,et al.  Improving protein identification from peptide mass fingerprinting through a parameterized multi‐level scoring algorithm and an optimized peak detection , 1999, Electrophoresis.

[32]  Jean-Charles Sanchez,et al.  Proteomics: new perspectives, new biomedical opportunities , 2000, The Lancet.

[33]  G I Murray,et al.  Proteomics: a new approach to the study of disease , 2000, The Journal of pathology.

[34]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[35]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Hochstrasser,et al.  Introduction to the Proteome , 1997 .

[37]  L. Liotta,et al.  Laser Capture Microdissection , 1996, Science.

[38]  E. Petricoin,et al.  New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. , 2001, Urology.

[39]  S Hanash,et al.  Proteomics in early detection of cancer. , 2001, Clinical chemistry.

[40]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[41]  Daniel Teichroew,et al.  Mining protein data from two‐dimensional gels: Tools for systematic post‐planned analyses , 1999 .

[42]  V. Sukhatme,et al.  Renal cancer: molecular mechanisms and newer therapeutic options , 2002, Current opinion in nephrology and hypertension.

[43]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[44]  M. Waltham,et al.  Identification of gel‐separated tumor marker proteins by mass spectrometry , 2000, Electrophoresis.

[45]  R D Appel,et al.  Computerized classification of two-dimensional gel electrophoretograms by correspondence analysis and ascendant hierarchical clustering. , 1988, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.

[46]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[47]  Robert F. Bonner,et al.  Laser Capture Microdissection: Molecular Analysis of Tissue , 1997, Science.